Vical: Collategene gets OK for late-stage trial

Vical's Japanese partner AnGes MG got a special protocol assessment approval from U.S. health regulators for a late-stage clinical trial of Collategene to treat peripheral arterial disease. The SPA provides a company with a written agreement that the design and analysis of the trial are adequate to support a marketing application submission to the FDA, Vical says. Report